Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Low Beta Blocker Dose Can Put Patients at Risk for Subsequent Heart Attacks

15.10.2010
Northwestern Medicine cardiologist part of breakthrough study of myocardial infarctions

For nearly 40 years a class of drugs known as beta blockers have been proven to increase patients’ survival prospects following a heart attack by decreasing the cardiac workload and oxygen demand on the heart.

In a breakthrough study released in the American Heart Journal, Northwestern Medicine cardiologist Jeffrey J. Goldberger found the majority of patients are frequently not receiving a large enough dose of these drugs, which can put their recovery from heart attacks and overall health into peril.

“Only 46% of patients studied were taking 50% or more of the target dose of beta blockers shown to be beneficial in clinical trials,” said Goldberger, director of cardiac electrophysiology research for the Bluhm Cardiovascular Institute of Northwestern Memorial Hospital and a professor of medicine at Northwestern University Feinberg School of Medicine. “Furthermore, 76% of patients were still being treated with the same amount of medication given at discharge. This means that for the vast majority of patients, there wasn’t even an attempt to increase their dose.”

Goldberger added that patients not getting the right amount of beta blockers is a problem nationwide. “Beta blockers work to keep patients alive after a heart attack, so proper dosing of beta blockers can save many lives,” said Goldberger.

Northwestern Memorial was one of 19 sites that participated in the PACEmaker and Beta-blocker Therapy Post-Myocardial Infarction (PACEMI) Trial Registry. Nearly 2,000 patients, who had been treated for a heart attack, were enrolled across the sites.

Study participants were prescribed very low doses at discharge, in part to assess how their bodies were likely to react to the drug. Researchers then followed up with patients three weeks later to determine if their personal physicians had adjusted the dosage amount.

“One of the reasons for the low dosage at discharge from the hospital can be attributed to patients’ shorter length of hospital stay,” said Goldberger. “Better communication between patients and their personal physicians would help ensure patients are receiving the appropriate dose of beta blockers more quickly. Patients can be in and out of the hospital within two days after a heart attack, and this short amount of time doesn’t allow for us to increase their medication to the target dose while they are still here.”

Goldberger added that there is not yet a system in place for what should happen as an outpatient that used to happen as an inpatient.

“Patients might see one doctor in the hospital but a different one in the office, and those two might not be conferring on the appropriate amount of beta blockers the patient should be taking,” said Goldberger.

These findings make it clear, Goldberger added, that patients and their personal physicians need to work together and have better communication.

“Patients also need to schedule an initial doctor’s appointment following their discharge within two weeks, so that doctors can adjust the amount of medication in a timely fashion,” said Goldberger. “I would expect 70-80% of patients to achieve 50% or more of the target dose.”

Media Contact
Jill McDonnell
Media Relations
(312) 926-0735
jimcdonn@nmh.org

Jill McDonnell | EurekAlert!
Further information:
http://www.nmh.org
http://www.nmh.org/nm/Beta+Blockers

More articles from Health and Medicine:

nachricht Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Strathclyde-led research develops world's highest gain high-power laser amplifier

The world's highest gain high power laser amplifier - by many orders of magnitude - has been developed in research led at the University of Strathclyde.

The researchers demonstrated the feasibility of using plasma to amplify short laser pulses of picojoule-level energy up to 100 millijoules, which is a 'gain'...

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

New insights into the ancestors of all complex life

29.05.2017 | Earth Sciences

New photocatalyst speeds up the conversion of carbon dioxide into chemical resources

29.05.2017 | Life Sciences

NASA's SDO sees partial eclipse in space

29.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>